Ilsung Pharmaceuticals Co., Ltd.

KSE 003120.KS

Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -5.93 M

Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure is USD -5.93 M for the year ending December 31, 2023, a 87.98% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -49.37 M, a -367.48% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -10.56 M, a -138.82% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -4.42 M, a -313.61% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -1.07 M, a 10.15% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 003120.KS

Ilsung Pharmaceuticals Co., Ltd.

CEO	Mr. Seok-geun Yoon
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	84-gil 9, Wonhyo-ro
Employees	224
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics

Description

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years